| Current Price | $79.46 | Mkt Cap | $199.1B |
|---|---|---|---|
| Open | $78.42 | P/E Ratio | 27.94 |
| Prev. Close | $79.46 | Div. (Yield) | $2.76 (3.5%) |
| Daily Range | $77.78 - $79.78 | Volume | 13,662,385 |
| 52-Wk Range | $68.38 - $91.40 | Avg. Daily Vol. | 14,277,620 |
A global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of innovative products to improve human and animal health.
| Current Price | $79.46 | Mkt Cap | $199.1B |
|---|---|---|---|
| Open | $78.42 | P/E Ratio | 27.94 |
| Prev. Close | $79.46 | Div. (Yield) | $2.76 (3.5%) |
| Daily Range | $77.78 - $79.78 | Volume | 13,662,385 |
| 52-Wk Range | $68.38 - $91.40 | Avg. Daily Vol. | 14,277,620 |
The best Bull and Bear pitches based on recency and number of recommendations.
Terrible leadership + atrocious decision making has fostered a culture of fear and indifference. Not sure how that bolsters the pipeline.
Read the most recent pitches from players about MRK.
Recs
DRRAB
(29.68)
Submitted: 10/1/2021 9:42:30 PM :
Start Price:
$84.17
NYSE:MRK Score:
-5.96
anti-viral pill for covid
Recs
publius200
(< 20)
Submitted: 10/1/2021 1:29:59 PM :
Start Price:
$82.10
NYSE:MRK Score:
-3.71
Introduction of Covid pill will increase stock price.
Recs
BOHICA101
(< 20)
Submitted: 9/28/2021 12:31:44 PM :
Start Price:
$73.43
NYSE:MRK Score:
+8.09
This stock has potential to take off.
Merck partnered with Ridgeback Biotherapeutics Ridgeback Biotherapeutics as they hold the rights to molnupiravir.
Their drug, molnupiravir, is one of two powerful medicines to treat COVID-19 that are nearing the end of clinical testing. Research suggested the compound could make it harder for the virus to replicate itself by interrupting the RNA polymerase enzyme, which acts like a copy machine for the viral genome. In various academic labs, molnupiravir has demonstrated activity against flu and many different types of coronavirus, including MERS and the common cold.
The hope is that it can stop the virus in its tracks, before it can replicate uncontrollably and cause a person to become more sick.
The U.S. government has agreed to purchase 1.7 billion doses at a cost of $1.2 billion if it passes Phase 3 and this would just be the beginning.
Also,
Merck is Reportedly Close to Buying Acceleron Pharma for 11 billion
Find the members with the highest scoring picks in MRK.
TrackTobinSmith (< 20) Score: +174.33
The Score Leader is the player with the highest score across all their picks in MRK.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| kaliblade | 85.22 | 2/12/2009 |
|
3W | $18.92 | +319.93% | +438.35% | +118.42 | 0 Comment | |
| prettymeadow | < 20 | 3/20/2009 |
|
3M | $17.51 | +353.85% | +457.53% | +103.68 | 0 Comment | |
| dbwhiz57 | < 20 | 12/17/2007 |
|
1Y | $36.83 | +115.75% | +213.83% | +98.08 | 0 Comment | |
| JoeySly | 88.54 | 3/6/2009 |
|
3W | $14.71 | +440.36% | +537.31% | +96.95 | 0 Comment | |
| fraley250r | < 20 | 1/7/2008 |
|
NS | $35.36 | +124.71% | +219.38% | +94.67 | 0 Comment | |
| bubba1986 | < 20 | 1/23/2008 |
|
3W | $30.69 | +158.95% | +252.23% | +93.28 | 0 Comment | |
| fordfest99 | 34.00 | 3/26/2009 |
|
3Y | $18.18 | +337.10% | +429.84% | +92.75 | 0 Comment | |
| buckywildcat | < 20 | 1/26/2009 |
|
1Y | $18.17 | +337.29% | +429.07% | +91.79 | 0 Comment | |
| stockpickeraz | 26.09 | 1/16/2009 |
|
5Y | $18.29 | +334.46% | +423.29% | +88.83 | 0 Comment | |
| TMFSpeck | 70.50 | 2/12/2010 |
|
5Y | $25.06 | +217.04% | +304.27% | +87.24 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
